FY2028 Earnings Estimate for BIO Issued By Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research issued their FY2028 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Monday, March 2nd. Zacks Research analyst Team forecasts that the medical research company will post earnings per share of $9.87 for the year. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter last year, the business earned $2.90 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis.

BIO has been the subject of several other reports. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $279.06 on Wednesday. The company has a fifty day simple moving average of $296.46 and a 200-day simple moving average of $301.19. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 10.00 and a beta of 1.18. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $343.12.

Institutional Trading of Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of BIO. First Eagle Investment Management LLC raised its holdings in shares of Bio-Rad Laboratories by 60.7% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock worth $607,478,000 after buying an additional 951,123 shares in the last quarter. Capital Research Global Investors acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at approximately $117,303,000. Massachusetts Financial Services Co. MA raised its position in shares of Bio-Rad Laboratories by 4,534.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock worth $120,956,000 after acquiring an additional 390,593 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Bio-Rad Laboratories by 2,271.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock worth $111,363,000 after purchasing an additional 380,422 shares during the last quarter. Finally, Boston Partners acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at $75,037,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.